Back

Interpreting and Validating a Deep Learning Model Predictive of Spatial Morphologic-Molecular Patterns in Lung Adenocarcinoma, Using Ground Truth Immunohistochemistry

Rao, V. R.; Workman, A. A.; Palisoul, S. M.; Limoge, C. J.; Vaickus, L. J.; Zanazzi, G. J.; Lu, L.; Liu, X.; Sukhadia, S. S.

2026-04-23 pathology
10.64898/2026.04.20.719723 bioRxiv
Show abstract

Lung adenocarcinoma (LUAD), the most common subtype of non-small cell lung cancer, exhibits profound histological and molecular heterogeneity. While genomic profiling has identified key oncogenic drivers and immune signatures, its use is limited by cost, technical demands and tissue availability. In addition, spatial transcriptomics provides spatially resolved molecular insights but remains challenging and time-consuming. To address this gap, we developed XpressO-Lung, an explanatory deep learning model that predicts gene expression heterogeneity spatially in tumor and its microenvironment on hematoxylin and eosin based diagnostic (Dx) whole-slide images (WSIs) by learning associations between tissue morphology and the corresponding bulk-transcriptomic data. Utilizing 200 LUAD cases from The Cancer Genome Atlas, XpressO-Lung predicted spatial expression patterns of NAPSA, TP53I3, CD8A, TTF1, KRT7, CDKN2A, FOXO1, KEAP1, RB1 and TP53 on Dx-WSIs with AUCs ranging from 0.64 to 0.92. The predicted spatial gene expression patterns aligned with the known morphologic interactions of the tumor and its microenvironment, capturing biological events directly on Dx-WSIs. These spatio-morpho-molecular associations were further validated using immunohistochemistry on an external set of clinical samples at Dartmouth Health, demonstrating concordance between model-predicted spatial patterns and observed histomorphologic features. By coupling predictive performance with spatial interpretability of gene expression on Dx-WSIs, the XpressO-Lung model bridges histopathology and bulk-transcriptomics, enabling explainable spatio-morpho-genomic analyses to advance biomarker discovery, therapeutic stratification and precision oncology in LUAD.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
Modern Pathology
21 papers in training set
Top 0.1%
17.9%
2
Clinical Cancer Research
58 papers in training set
Top 0.1%
13.8%
3
Cancer Research
116 papers in training set
Top 0.2%
6.6%
4
Journal of Pathology Informatics
13 papers in training set
Top 0.1%
6.1%
5
Nature Communications
4913 papers in training set
Top 35%
4.7%
6
The Lancet Digital Health
25 papers in training set
Top 0.2%
3.5%
50% of probability mass above
7
npj Digital Medicine
97 papers in training set
Top 1%
3.5%
8
npj Precision Oncology
48 papers in training set
Top 0.2%
3.1%
9
Scientific Reports
3102 papers in training set
Top 40%
3.1%
10
eBioMedicine
130 papers in training set
Top 0.5%
3.0%
11
PLOS ONE
4510 papers in training set
Top 51%
1.8%
12
Cell Reports Medicine
140 papers in training set
Top 4%
1.6%
13
Nature Cancer
35 papers in training set
Top 0.9%
1.6%
14
JNCI Cancer Spectrum
10 papers in training set
Top 0.3%
1.4%
15
JCO Clinical Cancer Informatics
18 papers in training set
Top 0.6%
1.3%
16
Breast Cancer Research
32 papers in training set
Top 0.4%
1.2%
17
The Journal of Pathology
22 papers in training set
Top 0.3%
1.2%
18
PLOS Computational Biology
1633 papers in training set
Top 20%
1.2%
19
Laboratory Investigation
13 papers in training set
Top 0.2%
0.9%
20
Cancers
200 papers in training set
Top 4%
0.9%
21
Science Advances
1098 papers in training set
Top 32%
0.7%
22
Clinical Chemistry
22 papers in training set
Top 0.9%
0.7%
23
BMC Cancer
52 papers in training set
Top 3%
0.7%
24
Cancer Medicine
24 papers in training set
Top 2%
0.7%
25
Nature Machine Intelligence
61 papers in training set
Top 4%
0.7%
26
iScience
1063 papers in training set
Top 36%
0.7%
27
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
28
JAMIA Open
37 papers in training set
Top 2%
0.6%
29
Cell Reports
1338 papers in training set
Top 36%
0.6%
30
Biomedicines
66 papers in training set
Top 4%
0.6%